Core Viewpoint - The XPLR Infrastructure class action lawsuit alleges that the company and its executives made misleading statements regarding its operations and financial health, leading to significant losses for investors during the specified class period [3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Alvrus v. XPLR Infrastructure, LP and involves purchasers of XPLR Infrastructure securities from September 27, 2023, to January 27, 2025, with a deadline of September 8, 2025, to seek lead plaintiff status [1]. - XPLR Infrastructure operates as a "yieldco," managing contracted clean energy projects, including wind and solar power, and a natural gas pipeline [2]. Group 2: Allegations Against XPLR Infrastructure - The lawsuit claims that XPLR Infrastructure struggled to maintain its yieldco operations and entered financing arrangements that were downplayed in terms of risk [3]. - It is alleged that the company could not resolve these financing issues without risking significant dilution of unitholder value, leading to a planned halt in cash distributions to investors [3]. - On January 28, 2025, XPLR Infrastructure announced the suspension of cash distributions and the abandonment of its yieldco model, resulting in a nearly 35% drop in the price of its common units [4]. Group 3: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased XPLR Infrastructure securities during the class period to seek lead plaintiff status, representing the interests of the class [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - The Ademi Firm is investigating DallasNews for potential breaches of fiduciary duty and other legal violations related to its transaction with Hearst [1][2]. Group 1: Transaction Details - Shareholders of DallasNews will receive $14.00 per share in cash as part of the transaction [2]. - DallasNews insiders are set to receive substantial benefits under change of control arrangements [2]. Group 2: Board Conduct - The transaction agreement imposes significant penalties on DallasNews if it accepts competing bids, which may limit competing transactions unreasonably [2]. - The investigation focuses on whether the DallasNews board of directors is fulfilling their fiduciary duties to all shareholders [2].

NEW YORK, July 10, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Krispy Kreme, Inc. (NASDAQ: DNUT) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Krispy Kreme caused the company to misrepresent or fail to disclose that (1) that demand for Krispy Kreme products declined materially at McDonald's locations after the initial marketing launch; (2) that demand at McDonald' ...

Core Viewpoint - The article discusses a class action lawsuit against Sarepta Therapeutics, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, during a specified class period [1][3]. Company Overview - Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing therapies for Duchenne muscular dystrophy, including the gene therapy ELEVIDYS [2]. Allegations of the Lawsuit - The lawsuit claims that Sarepta and its executives made false or misleading statements about ELEVIDYS, including significant safety risks, failure to detect severe side effects, and the potential for halting clinical trials due to adverse events [3]. - Specific incidents cited include: - On March 18, 2025, a patient treated with ELEVIDYS suffered acute liver failure leading to death, causing Sarepta's stock to drop over 27% [4]. - On April 4, 2025, Sarepta disclosed that EU authorities requested a review of the death, leading to a further stock decline of over 7% [5]. - On June 15, 2025, a second patient died from acute liver failure, prompting Sarepta to suspend shipments and pause dosing, resulting in a stock drop of over 42% [6]. - On June 24, 2025, the FDA announced an investigation into the risk of acute liver failure associated with ELEVIDYS, causing an additional stock decline of over 8% [7]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Sarepta securities during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [8].

NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Civitas Resources, Inc. (NYSE: CIVI) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Civitas Resources caused the company to misrepresent or fail to disclose that (i) Civitas was highly likely to significantly reduce its oil production in 2025 as a result of, inter alia, declines following the produc ...

NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Open Lending Corporation (NASDAQ: LPRO) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Open Lending caused the company to misrepresent or fail to disclose that (1) the Company’s risk-based pricing models; (2) the Company’s profit share revenue; (3) failed to disclose the Company’s 2021 and 2022 vint ...

MILWAUKEE, July 8, 2025 /PRNewswire/ -- The Ademi Firm is investigating CARGO (NASDAQ: CRGX) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra Biosciences.Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.In the transaction, shareholders of CARGO will receive $4.379 in cash per share, plus one non-transferable contingent va ...

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of NET Power Inc. (NYSE: NPWR) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at NET Power caused the company to misrepresent or fail to disclose that (i) Net Power was unlikely to complete Project Permian on schedule, and the project was likely to be significantly more expensive than had been represented ...

SAN DIEGO, July 1, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc. (NASDAQ; SRPT) securities between June 22, 2023 and June 24, 2025, both dates inclusive (the "Class Period"), have until August 25, 2025 to seek appointment as lead plaintiff of the Sarepta class action lawsuit.  Captioned Dolgicer v. Sarepta Therapeutics, Inc., No. 25-cv-05317 (S.D.N.Y.), the Sarepta class action lawsuit charges Sarepta as well as certain of Sarepta' ...

MILWAUKEE, June 30, 2025 /PRNewswire/ -- The Ademi Firm is investigating GMS (Nasdaq: GMS) for possible breaches of fiduciary duty and other violations of law in its transaction with Home Depot.Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.In the tender offer transaction, shareholders of GMS will receive $110 per share, reflecting a total equity value of approximately $4 ...